Top

Clinical and Translational Oncology

Published in:

01-09-2018 | Research Article

Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger

Authors: X. Pan, T. Lv, F. Zhang, H. Fan, H. Liu, Y. Song

Published in: Clinical and Translational Oncology | Issue 9/2018

Abstract

Background

The subgroup of young patients with non-small-cell lung cancer (NSCLC) is poorly understood. We retrospectively studied the clinical characteristics, gene mutations, and outcomes of patients with NSCLC (aged ≤ 40 years).

Results

Of the 7494 patients with lung cancer diagnosed from February 2001 to October 2016, 252 aged ≤ 40 years showed NSCLC. We divided their cases into non-squamous cell carcinoma and squamous cell carcinoma groups according to their histology results. Of the 252 young NSCLC patients, 173 (69%) patients had stage IIIB or IV, and 196 (78%) had never smoked. The four most common metastases were intrapulmonary lesions, pleura, bone, and brain. Among patients with adenocarcinoma, 29 (40%, n = 73) harbored epidermal growth factor receptor (EGFR) mutations, 25 (34%, n = 74) harbored anaplastic lymphoma kinase (ALK) translations, and 1 (14%, n = 7) harbored ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) translations. The median progression-free survival (PFS) and overall survival (OS) were 3.3 and 27.6 months for patients receiving chemotherapy (n = 65), and 12.1 and 33.6 months for patients receiving EGFR tyrosine kinase inhibitors (TKIs) (n = 13), respectively. Patients receiving crizotinib had a median PFS time of 21.9 months (n = 8).

Conclusions

Young patients are associated with an increased likelihood of gene mutations and can receive a better prognosis when patients harboring gene mutations are treated with EGFR-TKIs or ALK inhibitors.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djx030.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed

Chen WZR, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016. https://doi.org/10.3322/caac.21338.PubMedCentralCrossRefPubMed

Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol. 2010;5(1):23–8. https://doi.org/10.1097/JTO.0b013e3181c41e8d.CrossRefPubMed

Thomas A, Chen Y, Yu T, Jakopovic M, Giaccone G. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol. 2015;5:113. https://doi.org/10.3389/fonc.2015.00113.CrossRefPubMedPubMedCentral

Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, et al. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Cancer. 2017;123(10):1731–40. https://doi.org/10.1002/cncr.30539.CrossRefPubMed

Sacher AG, Dahlberg SE, Heng J, Mach S, Janne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. Jama Oncol. 2016;2(3):313–20. https://doi.org/10.1001/jamaoncol.2015.4482.CrossRefPubMedPubMedCentral

Lara MS, Brunson A, Wun T, Tomlinson B, Qi L, Cress R, et al. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer. 2014;85(2):264–9. https://doi.org/10.1016/j.lungcan.2014.04.007.CrossRefPubMed

Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015;372(7):683–4. https://doi.org/10.1056/NEJMc1415359.CrossRefPubMed

10.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–9. https://doi.org/10.1093/annonc/mdv270.CrossRefPubMed

11.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77. https://doi.org/10.1056/NEJMoa1408440.CrossRefPubMed

12.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8. https://doi.org/10.1056/NEJMoa0909530.CrossRefPubMed

13.

Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, et al. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. BMC Cancer. 2012;12:241. https://doi.org/10.1186/1471-2407-12-241.CrossRefPubMedPubMedCentral

14.

Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, et al. Lung cancer in the very young: treatment and survival in the national cancer data base. J Thorac Oncol. 2016;11(7):1121–31. https://doi.org/10.1016/j.jtho.2016.03.023.CrossRefPubMed

15.

Zhang J, Chen SF, Zhen Y, Xiang J, Wu C, Bao P, et al. Multicenter analysis of lung cancer patients younger than 45 years in Shanghai. Cancer. 2010;116(15):3656–62. https://doi.org/10.1002/cncr.25100.CrossRefPubMed

16.

Rich AL, Khakwani A, Free CM, Tata LJ, Stanley RA, Peake MD, et al. Non-small cell lung cancer in young adults: presentation and survival in the english national lung cancer audit. QJM. 2015;108(11):891–7. https://doi.org/10.1093/qjmed/hcv052.CrossRefPubMed

17.

Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, et al. Advanced non-small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer. 2016;98:99–105. https://doi.org/10.1016/j.lungcan.2016.05.020.CrossRefPubMed

18.

Scarpino S, Rampioni Vinciguerra GL, Di Napoli A, Fochetti F, Uccini S, Iacono D, et al. High prevalence of ALK⁺/ROS1⁺ cases in pulmonary adenocarcinoma of adolescents and young adults. Lung Cancer. 2016;97:95–8. https://doi.org/10.1016/j.lungcan.2016.04.022.CrossRefPubMed

19.

Nagashima O, Ohashi R, Yoshioka Y, Inagaki A, Tajima M, Koinuma Y, et al. High prevalence of gene abnormalities in young patients with lung cancer. J Thorac Dis. 2013;5(1):27–30. https://doi.org/10.3978/j.issn.2072-1439.2012.12.02.PubMedPubMedCentralCrossRef

20.

Corrales-Rodriguez L, Arrieta O, Mas L, Baez-Saldana R, Castillo-Fernandez O, Blais N, et al. An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). Lung Cancer. 2017;113:30–6. https://doi.org/10.1016/j.lungcan.2017.08.022.CrossRefPubMed

21.

Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96:101–7. https://doi.org/10.1016/j.lungcan.2016.04.004.CrossRefPubMed

22.

Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195–9. https://doi.org/10.1097/JTO.0000000000000069.CrossRefPubMed

23.

Takano K, Kinoshita M, Takagaki M, Sakai M, Tateishi S, Achiha T, et al. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor. Neuro Oncol. 2016;18(5):716–24. https://doi.org/10.1093/neuonc/nov266.CrossRefPubMed

Title: Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger
Authors: X. Pan
T. Lv
F. Zhang
H. Fan
H. Liu
Y. Song
Publication date: 01-09-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 9/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1838-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2018

Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation

Circular RNAs and exosomes in cancer: a mysterious connection

miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1

Pancreaticoduodenectomy for periampullary tumours: a review article based on Surveillance, End Results and Epidemiology (SEER) database

Radiotherapy in soft-tissue sarcoma of the extremities

Integral nutritional approach to the care of cancer patients: results from a Delphi panel

Keynote webinar | Spotlight on antibody–drug conjugates in cancer